Burning feet at night. Pins and needles that never quite go away. Skin that hurts when a bedsheet touches it. If that sounds familiar, you have probably also had the conversation where a doctor runs a nerve conduction test, finds nothing, and shrugs.
That gap is where ARA-290 gets interesting. Most peptides sold online have animal studies and a good story. This one has been through randomized, placebo-controlled human trials under the pharmaceutical name cibinetide, and in those trials it did something almost nothing else in this market can claim. It grew nerve fibers back.
What most articles on this compound will not tell you is this. The nerve regrowth is real and statistically solid. The pain relief is a messier story, with one major trial missing its pain endpoint outright. Anyone selling you a clean, simple “it kills pain” narrative is skipping the part of the data that matters most if you are the one deciding whether to try it.
This guide walks through every human trial that measured pain, skipping none of the ones that make bad marketing copy, explains why relief (when it happens) tends to build slowly rather than hit fast, breaks down dosing exactly as researchers used it, covers reconstitution as concentration math rather than instructions, and tells you plainly where the evidence stops.
The BrainFlow Take
ARA-290 has an unusually solid evidence base for a research peptide. Randomized trials in sarcoidosis patients showed measurable regrowth of small nerve fibers, a structural change confirmed by imaging, not just a symptom score moving. That part of the story is strong. The pain relief itself is more nuanced. In the largest trial, the pain endpoint did not reach statistical significance, and in two earlier studies, pain scores improved about as much on placebo as on the drug. That does not mean ARA-290 does nothing for pain. It means the honest picture is a repair-focused peptide with real structural evidence and a pain benefit that is plausible, mechanistically sound, and still short of proven. Anyone telling you pain will become “near non-existent” is overselling a compound that deserves a fairer, more precise pitch than that.
ARA-290 at a glance
- An 11-amino-acid peptide copied from a specific surface of the erythropoietin (EPO) molecule
- Known as cibinetide in clinical research, the exact same compound under its pharmaceutical name
- Activates the innate repair receptor, a repair-and-calm-inflammation switch that appears on injured tissue
- Non-erythropoietic, meaning it does not raise red blood cells the way EPO does
- Best evidence is structural nerve fiber regrowth in sarcoidosis-related neuropathy. The direct pain-relief evidence is real but mixed, including one trial that missed its pain endpoint
- Investigational everywhere. Not approved by the FDA, EMA, MHRA, Health Canada, or the TGA, and development has stalled with no active trial sponsor
- Injectable in every human trial. No meaningful oral or nasal data exists
Before the deep dive, a practical note for anyone already sold. The best-value source we have found is Amino Club’s ARA-290, tested 7 times with full certificates of analysis on every batch. It runs $49.99 for 10mg and comes down to about $39.99 with code BRAINFLOW. Now, the full picture, including the parts that do not make for great sales copy.
What ARA-290 Really Is
ARA-290 is a short synthetic peptide, 11 amino acids long, with the sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. It was built to copy one specific patch on the surface of erythropoietin, the hormone your kidneys use to tell bone marrow to make red blood cells. Erythropoietin itself is a much larger molecule, 165 amino acids, so ARA-290 is not a fragment of the whole thing so much as a targeted recreation of one useful piece.
The patch it copies is called helix B, which is why you will also see it written as helix B surface peptide or pHBSP. That region of EPO is not the part that talks to the red-cell machinery, and that distinction is the entire point of the drug.
One naming point trips up almost everybody, including some of the pages you will find ranking for this topic. ARA-290 and cibinetide are the same molecule. “ARA-290” is the development code from Araim Pharmaceuticals. “Cibinetide” is the official international nonproprietary name used in trials and regulatory filings. When you read a clinical paper about cibinetide, you are reading about ARA-290.
Michael Brines and Anthony Cerami designed it deliberately rather than discovering it by accident. Their earlier work established that EPO’s protective effects on tissue run through a different receptor than its blood-building effects, and their 2008 paper in PNAS showed that short peptides built from the helix B surface kept the protective signal on its own. ARA-290 came directly out of that line of work.
Worth knowing before you go further, some vendor and blog pages list a 15-amino-acid sequence for ARA-290. That is simply wrong. Chemical databases including PubChem list it as 11 amino acids, CAS number 1208243-50-8, molecular formula C51H84N16O21.
Research-grade ARA-290
Amino Club ARA-290 10mg, Tested 7x
ARA-290 is a peptide where sourcing matters more than usual, because identity and purity are the whole ballgame with an 11-amino-acid compound, and some sellers cannot even get the sequence right on their own product page. Amino Club tests every batch 7 times and publishes full COAs so you can verify what is in the vial before it ships. The 10mg runs $49.99 and drops to about $39.99 with code BRAINFLOW.
Shop ARA-290 → Save 20%Use code BRAINFLOW for 20% off. Tested 7x with full COAs. Sold for research use only.
EPO and the Innate Repair Receptor, Explained Simply
Erythropoietin has two jobs, and almost nobody knows about the second one.
The famous job is making red blood cells. That is why EPO became infamous in cycling, and why synthetic EPO treats anemia. But when tissue anywhere in your body gets injured or inflamed, cells nearby produce their own EPO locally, and it acts as a protect-and-repair signal. It tells damaged cells to stay alive and tells the immune response to stop overreacting.
Those two jobs travel through two different receptors. Red-cell production runs through a pair of identical EPO receptor units locked together. Tissue protection runs through a mismatched pair, one EPO receptor unit joined to a partner protein called CD131, also known as the beta common receptor. Brines and Cerami named that second combination the innate repair receptor.
Picture EPO as a loudspeaker announcement that goes out to the whole building. Some of the message is “make more blood,” and some of it is “repair the damage in room 12.” Useful, but you cannot send one part without the other, and cranking the volume brings side effects like thickened blood and clot risk. ARA-290 is the repair sentence clipped out of that announcement and delivered as a note slipped under the door of room 12.
The receptor has one more feature that makes this whole approach clever. It barely shows up on healthy resting tissue and gets switched on where cells are injured, inflamed, or under metabolic stress. So a drug that targets it tends to act where there is damage rather than everywhere at once.
Two things to keep straight. EPO-derived does not mean it behaves like EPO. The entire design goal was to keep the repair signal and drop the red-cell push, and every human trial confirmed hemoglobin and hematocrit stayed flat. And “nerve repair peptide” is a great phrase that flattens a more specific truth, which the next two sections unpack in full.
How ARA-290 Works
Once ARA-290 binds the innate repair receptor, it sets off a chain of events on the cells that carry it, which includes blood vessel lining, immune cells, glial cells, and neurons in damaged tissue. Survival pathways switch on. Inflammatory signaling calms down. The local environment shifts away from ongoing injury and toward resolution.
Two more specific mechanisms explain why this matters for pain, and they come from separate lines of animal research that both point at the same receptor.
The first runs through the spinal cord itself. When a nerve is injured, immune cells inside the spinal cord called microglia get stuck in an activated state, and they keep amplifying pain signals long after the original injury has healed. This is a major driver of chronic neuropathic pain, and it is largely separate from whatever is happening at the site of injury. Swartjes and colleagues, writing in Molecular Pain, gave rats with nerve injuries a range of ARA-290 doses over ten days and found dose-dependent relief of mechanical and cold sensitivity that lasted up to twenty weeks, alongside a measurable drop in that spinal microglia activation. A separate paper from the same group found the pain relief disappeared entirely in mice bred without CD131, confirming the effect runs specifically through the innate repair receptor rather than some off-target action.
The second mechanism sits closer to the nerve ending itself. Zhang and colleagues in the journal Peptides found that ARA-290 directly dampens a channel called TRPV1, the same heat-and-chemical sensor that capsaicin activates, and that this reduced pain hypersensitivity triggered experimentally in nerve cells. So the compound appears to be working on pain from two directions at once, calming the amplifier in the spinal cord and turning down the sensor on the nerve itself.
Evidence quality splits sharply from this point, and the split matters:
- Confirmed in humans. Innate repair receptor engagement without red-cell stimulation, and increased small nerve fiber density on the cornea.
- Confirmed in animals, unconfirmed in people. Spinal microglia suppression, TRPV1 modulation, cytokine reduction, and macrophage modulation.
- Animal only. Kidney and heart protection during ischemia, wound healing, retinal blood vessel repair, and pancreatic islet protection.
- Mechanistic guesswork. Broad longevity, recovery, and brain fog claims. These sound plausible given the biology and have no ARA-290 human data whatsoever.
One pharmacology detail explains a lot about the dosing and timing you will see later. ARA-290 clears from the blood fast. Estimates vary by source, with one pharmacokinetic review putting the plasma half-life around two minutes and other reports describing a terminal half-life closer to twenty minutes. Either way, the drug itself does not stick around long. What lasts is the gene-expression change it triggers through the receptor, which is why effects build over days rather than appearing the moment it is injected.
ARA-290 for Chronic and Neuropathic Pain: What the Trials Show
This is the section worth reading slowly if pain is the reason you are here. Four human trials measured pain-related outcomes, and the honest picture is more textured than any single number can capture. Structural nerve regrowth came through clearly and consistently. Direct pain relief came through in some measures and not others, sometimes in the same trial.
The earliest signal: Heij 2012
This pilot study enrolled 22 sarcoidosis patients with small fiber neuropathy symptoms, split between ARA-290 and placebo, dosed intravenously three times a week for four weeks. A symptom questionnaire called the SFNSL improved significantly more on the drug than on placebo. But two other measures, a standard pain inventory and a fatigue scale, improved by similar amounts in both groups. That pattern, some measures separating from placebo and others not, shows up again in every larger trial that followed.
Dahan 2013: the trial with the clearest story
This trial is the one most worth understanding in detail, because it is where the case for ARA-290 is strongest and also where the nuance between different kinds of pain measurement shows up most clearly. Thirty-eight sarcoidosis patients received either 4mg subcutaneously once a day for 28 days or placebo, with follow-up tracking out to nine months.
The symptom score improved by roughly a third on the drug versus under a tenth on placebo, a difference that easily cleared statistical significance. Eighty-one percent of treated patients hit a meaningful symptom improvement compared to less than half on placebo. A measure of how much pain interfered with daily function also separated clearly from placebo. Cold and heat pain thresholds, tested objectively rather than self-reported, improved significantly on the drug and did not move on placebo. Patients walked farther in a six-minute test. And the corneal imaging, the structural nerve marker, showed a genuine 14.5 percent increase in nerve fiber area on the drug against a slight decline on placebo.
The part that gets left out of most summaries is this. When researchers looked specifically at raw pain intensity, rather than pain interference or the broader symptom score, both groups improved by about the same amount, roughly nine percent from baseline. That is a placebo-level response on that particular measure, sitting right alongside real, drug-driven improvements on several other measures in the same study. Pain is not one thing you can measure with a single number, and this trial is a good demonstration of why.
The durability finding stands out most. The symptom score benefit was still statistically significant nine months after the 28-day treatment ended, which is rare for any pain intervention and fits the idea that this is a slow repair process rather than a drug masking sensation while it is in your system. By that nine-month mark, though, the pain interference measure and the walking-distance improvement had faded and were no longer statistically different from placebo. The durable part of the benefit was the symptom score, not every measure that improved at 28 days.
DOSARA 2017: the nerves regrew, but the pain endpoint fell short
This is the trial that should anchor how you think about ARA-290 and pain, because it was the largest, most rigorously designed study, registered at ClinicalTrials.gov as NCT02039687 and published in Investigative Ophthalmology and Visual Science. Sixty-four sarcoidosis patients with painful neuropathy were randomized to 1mg, 4mg, or 8mg daily, or placebo, for 28 days.
The nerve fiber structural endpoint, the trial’s actual primary goal, was met at the 4mg dose. Corneal nerve fiber area increased significantly compared to placebo, and a separate marker of actively regenerating fibers rose by about 23 percent from baseline. Doubling the dose to 8mg added nothing over 4mg, a useful signal that this is not a more-is-better compound.
Pain was a secondary endpoint, and this is where the trial’s own published results are direct. In the subgroup of patients with moderate to severe pain going in, the placebo-corrected drop in pain intensity at 4mg did not reach statistical significance. Researchers reported the difference as clinically suggestive but not statistically confirmed. That is a missed endpoint, stated plainly rather than reframed as a win.
It is worth sitting with what that means rather than throwing the whole trial out. The structural regrowth endpoint, measured by objective imaging, succeeded. The subjective pain-intensity endpoint, measured by patient report in a small subgroup over just 28 days, did not. Those two things can both be true, and they point toward a compound that changes nerve biology in a way pain relief may eventually follow from, without that trial proving pain relief on its own terms.
Brines 2015: the diabetes surprise
This smaller trial shifted the population from sarcoidosis to type 2 diabetes with painful neuropathy, using the same 4mg daily dose for 28 days. A validated neuropathic pain screening tool improved significantly on the drug. Unexpectedly, blood sugar control also improved, with HbA1c dropping in a way that reached statistical significance, alongside better cholesterol and triglyceride numbers. Corneal nerve fiber density rose in the subset of patients who started with reduced fiber counts. This is one small, likely underpowered study, and it deserves to be read as an interesting lead rather than a settled finding, but it is the trial that opened the door to thinking about ARA-290 beyond sarcoidosis.
Why pain relief shows up slowly and lasts
Put the mechanism and the trial pattern side by side and a coherent story emerges. ARA-290 does not block pain signals the way an opioid or a local anesthetic does. It appears to work upstream, calming the spinal microglia that keep chronic pain circuits switched on and quieting the TRPV1 sensor on nerve endings, while separately encouraging small fibers to regrow. None of that happens in minutes. It happens over days as gene expression shifts and tissue slowly remodels, which is exactly the pattern the trials show, structural and function measures moving steadily over 28 days, with the most durable trial follow-up showing benefit still present nine months later.
That also explains why raw pain-intensity scores are the least reliable measure across these trials. Intensity ratings are noisy, highly responsive to placebo, and sensitive to a single bad or good day. Structural imaging and validated symptom-interference scores are more stable and less prone to expectation effects, and those are exactly the measures where ARA-290 consistently separated from placebo.
What Kinds of Pain ARA-290 Is Likely, and Not Likely, to Help
Every trial ever run tested one of two populations, and being honest about that scope matters more than any mechanism discussion.
- Studied in controlled human trials: sarcoidosis-associated small fiber neuropathy, across three separate trials, and type 2 diabetic painful neuropathy, in one trial.
- Not studied in any controlled human pain trial: fibromyalgia, complex regional pain syndrome, chemotherapy-induced peripheral neuropathy, post-surgical pain, low back pain, arthritis or osteoarthritis pain, long COVID-related pain, and erythromelalgia.
Fibromyalgia deserves a specific note, since it comes up constantly in community discussion and even in podcast interviews with longevity physicians. The mechanistic argument is not crazy. A meaningful subset of fibromyalgia patients do show small fiber neuropathy on biopsy, which is exactly the tissue pattern ARA-290 was designed to address. But that is a hypothesis built on overlap, not a trial result. Nobody has run a controlled study of ARA-290 in fibromyalgia, and treating community enthusiasm as evidence would be a mistake.
The pattern across every trial points toward one type of pain this compound is built for, pain coming from small, damaged nerve fibers, tied to an underlying inflammatory or metabolic process. Pain from mechanical injury, structural joint damage, or a source unrelated to nerve fiber loss sits outside anything these trials tested, and there is no biological reason to expect the same mechanism would apply.
The Human Trials at a Glance
Add it all up and total human exposure across every ARA-290 trial ever run sits at roughly 100 to 130 patients, all at one or two centers, none longer than twelve weeks, with no Phase 3 and the developer now inactive. That is a real evidence base by research-peptide standards and a thin one by pharmaceutical standards. Both statements are true at once.
ARA-290’s Other Potential Benefits
Nerve fiber regrowth and pain relief are not the whole story, though they are the part with the most human data behind them. A handful of other benefit categories come up constantly in ARA-290 discussion, and they deserve the same honest treatment.
Inflammation control is the mechanistic backbone of everything else. The innate repair receptor sits on macrophages, microglia, and T cells, and animal models covering colitis, multiple sclerosis, lupus, and arthritis all show reduced inflammatory markers when ARA-290 is given. What has never happened is a human trial where inflammation itself was the primary thing being measured. So when you see it marketed as a broad anti-inflammatory peptide, that claim is riding on mouse data and receptor biology, plausible but unproven in people.
Wound healing and organ protection show some of the most compelling animal work in the entire ARA-290 literature, and also the widest gap between animal and human evidence. Better wound healing in diabetic mice, improved kidney function after blood flow interruption in pigs, protection of transplanted pancreatic islets, and repair of damaged retinal blood vessels have all been demonstrated. None of it has been tested in a human being taking ARA-290. File it as animal-only, full stop, no matter how many times you see it cited as a settled benefit.
Recovery, longevity, and brain fog claims are the ones driving most of the biohacking interest, and they rest on the thinnest ground of anything covered here. One animal healthspan study exists. Zero human data exists in healthy people using ARA-290 for any of these purposes. Anyone framing this as a proven longevity or recovery compound is extrapolating from sick trial participants to an entirely different population that has never been studied.
ARA-290 Dosage in Research
Because people search for ARA-290 dosage, this section summarizes doses used in clinical trials, preclinical research, and commonly discussed online protocols. This is not a personal dosing recommendation.
Trial dosing converged remarkably tightly. Nearly every human study landed on the same number, and it is worth being precise here since you will encounter pages online quoting different, unsourced figures:
- 4mg subcutaneous daily was the dose in Dahan 2013, Brines 2015, DOSARA, and the macular edema pilot. It is the most studied dose by a wide margin, and the dose that produced the primary structural result in DOSARA.
- 2mg intravenous three times weekly was used in the earliest 2012 pilot.
- 1mg and 8mg were tested head-to-head against 4mg in DOSARA. The 1mg dose underperformed, and 8mg produced no additional benefit over 4mg, meaning higher was not better.
- Trial duration was 28 days in most studies, with the longest running 12 weeks.
- Animal studies used roughly 3 to 60 micrograms per kilogram, with effects appearing at the higher end of that range.
- Community protocols reported on forums typically mirror the trial numbers, usually 1 to 4mg daily in cycles of about 28 days.
Three clarifications that prevent expensive mistakes. Pharmaceutical cibinetide and research-market ARA-290 are not interchangeable, because the trial material was manufactured under pharmaceutical quality controls with verified sterility and potency. Trial dosing is documentation of what researchers administered under medical supervision, not instructions. And vial size is not dose, a confusion so common it deserves its own section below.
On routes, injection is the only one with human evidence. Subcutaneous dominated the trials, with intravenous used early on. Oral and nasal ARA-290 have no meaningful human data, and an 11-amino-acid peptide faces real problems surviving the digestive tract.
ARA-290 Reconstitution and Concentration Math
Reconstitution math is simply concentration math. It does not establish whether a product should be used, what dose is appropriate, whether a vial is sterile, or whether research material is equivalent to clinical-trial cibinetide. What follows explains the arithmetic people are searching for, nothing more.
Two conversions do most of the work. One milligram equals 1000 micrograms. And concentration in mg per mL equals the vial’s milligrams divided by the millilitres of liquid added. That is the whole formula.
The syringe part confuses people more than it should. On a U-100 insulin syringe, 100 units equals 1 mL. So one unit is 0.01 mL and ten units is 0.1 mL. Units measure volume, not peptide. The same ten units contains completely different amounts of ARA-290 depending on how concentrated the solution is.
Read that table as arithmetic, not advice. If someone adds 2 mL to a 10mg vial, the concentration is 5 mg/mL. That math does not mean 2 mL is the right choice, and a different vial size or volume changes every number in the row.
The mistakes that come up over and over:
- Treating vial size as dose. A 10mg vial is total peptide in the container, not one serving.
- Mixing up mg and mcg, a 1000-fold error that is the single most dangerous math slip in this space.
- Assuming “10 units” is a universal amount. It is a volume, and it means different things at different concentrations.
- Adding too little liquid, which makes draws tiny and measurement error large.
- Assuming research-vial instructions match what happened in a clinical trial. They do not.
- Ignoring sterility, storage temperature, and degradation, which is where gray-market material carries genuine risk.
Worth stating plainly, research-market vials are sold for laboratory use only and are not quality-assured for human use. Clinical cibinetide was a sterile pharmaceutical product with verified identity, purity, and stability. Those are different things regardless of what the label says.
Verified sourcing
Amino Club ARA-290, Full COAs on Every Batch
Identity and purity are everything with a peptide this short, and plenty of vendors have been caught selling the wrong sequence entirely. Amino Club runs 7 rounds of testing per batch and publishes the certificates so you can check before you buy. 10mg for $49.99, about $39.99 with code BRAINFLOW.
Get ARA-290 → Save 20%Code BRAINFLOW takes 20% off. Sold for research use only.
Side Effects and Safety
You will sometimes see it claimed online that not a single ARA-290 study has ever reported a side effect. That is not accurate, and it is worth correcting directly, because the real safety record is good enough that it does not need embellishing.
Across trials, the most commonly reported effects were mild, injection site soreness or redness, headache in roughly 14 to 19 percent of treated patients in DOSARA compared to none on placebo, and scattered reports of dizziness, fatigue, nausea, and diarrhea. Hemoglobin and hematocrit stayed flat throughout, confirming the non-erythropoietic design worked as intended, and no anti-drug antibodies were detected in the trial that tested for them.
The DOSARA trial also recorded three serious adverse events, and reporting them plainly is part of giving you the full picture. Two patients in the lowest-dose group experienced syncope, headache, and enteritis, judged by investigators as unrelated to treatment. One patient in the highest-dose group, 8mg, experienced suicidal ideation that investigators judged possibly related to treatment. No serious adverse events occurred in the 4mg group, the dose that produced the trial’s positive structural result, or during the Dahan 2013 sarcoidosis trial’s dosing period or twelve-week follow-up. A single case in a small trial does not establish a causal link, but it is a real signal worth knowing about rather than a hypothetical one.
The bigger gaps are not effects that showed up, but questions nobody has answered. No trial ran past twelve weeks, so long-term safety is unknown. Nobody has studied pregnancy, breastfeeding, children, drug interactions, or repeated cycles. Roughly 100 to 130 people total have taken this compound in a controlled setting, a small number for catching anything rare.
And there is one risk that has nothing to do with the molecule itself, which is product quality. Unverified vials can carry the wrong compound, wrong concentration, contamination, or degraded material, entirely separate from anything the clinical trials measured.
Who Should Steer Clear
Given the evidence gaps, several groups have no business experimenting here. Anyone pregnant or breastfeeding, since zero data exists. Anyone under 18, for the same reason. Anyone with an active cancer diagnosis should discuss it with their oncologist first, since growth and repair signaling in that context deserves professional input. People with autoimmune conditions on immune-modulating drugs face unknown interactions.
Anyone with a personal or family history of mental health crisis deserves an extra note. One patient in the highest-dose arm of the DOSARA trial reported suicidal ideation that investigators judged possibly related to treatment. That single case in a small trial does not prove a causal link, but it is exactly the kind of finding that argues for medical supervision rather than solo experimentation, and for taking any unusual mood changes seriously if they appear.
And anyone hoping this substitutes for approved neuropathy treatment should understand it has never been compared head to head against gabapentin, duloxetine, or any of the treatments that carry real approval.
Legal and Regulatory Status
ARA-290 is not approved as a medicine anywhere in the world. Not by the FDA, EMA, MHRA, Health Canada, or the TGA. No new drug application was ever filed.
It does hold orphan drug designation in both the US and EU for sarcoidosis-related indications, granted in 2016, plus US Fast Track designation for neuropathic pain in sarcoidosis, granted in 2014. Those designations get misrepresented constantly. They are development incentives that reduce fees and speed up review for rare diseases. They are not approvals, and they do not mean a regulator has concluded the drug works.
Development has stalled since the DOSARA results were published. No Phase 3 trial was ever registered, and Araim Pharmaceuticals, the company that developed the compound, is no longer active. No sponsor currently holds an open investigational drug application for ARA-290 in the United States. That does not erase the Phase 2 results, but it means nobody is currently working to confirm them at a larger scale, and it means the compound’s regulatory timeline has effectively frozen.
It is not a dietary supplement and cannot legally be one. It is sold as a research chemical for laboratory use only, and marketing it with claims about treating neuropathy, pain, or inflammation invites FTC action. Athletes should also note that while ARA-290 is specifically non-erythropoietic, anything EPO-adjacent deserves caution under anti-doping rules covering non-approved substances.
ARA-290 Compared to Standard Pain Treatments
The comparison that matters most is not against other trendy peptides. It is against everything someone with nerve pain might realistically be offered at a doctor’s visit.
The distinction worth carrying away is this. Opioids block signals fast and leave the underlying nerve damage untouched. Gabapentin and duloxetine work more slowly but are still purely symptomatic, quieting pain perception without addressing what caused it. Low-dose naltrexone is the closest philosophical cousin to ARA-290, since it also works by calming overactive glial cells rather than blocking sensation outright, though the two compounds act on different receptors. ARA-290’s entire pitch is that it goes further than any of these, targeting the damaged tissue itself. That pitch has real supporting evidence for the structural side and weaker, mixed evidence for pain relief specifically. It does not replace approved treatment, and nobody has run the head-to-head trial that would settle how it stacks up directly.
What People Stack It With
Community stacking chatter follows predictable logic, though almost none of it has been formally studied in combination. People pair ARA-290 with BPC-157 or TB-500 on a general repair theory, with KPV for layered anti-inflammatory effects, and with mitochondrial compounds like MOTS-c or SS-31 on the reasoning that nerve repair is energy-expensive.
The most defensible pairing is the least exotic one. For diabetic neuropathy, combining anything with actual glucose control does more than any peptide stack, because uncontrolled blood sugar is the thing damaging the nerves in the first place. Alpha-lipoic acid, benfotiamine, and acetyl-L-carnitine all have their own neuropathy trial data and get combined with ARA-290 for that reason.
Stacking has one underappreciated cost. Run four compounds at once and you lose the ability to tell which one did anything, including which one caused a side effect.
What Users Report
Treat everything in this section as anecdote, because that is what it is. Forum and community reports are not evidence, and they skew toward people motivated to post.
The most common positive reports come from people with diagnosed neuropathy describing reduced burning and tingling. Onset usually falls across two to three weeks rather than happening right away, which lines up with the trial timelines. A meaningful number of people report nothing at all. Mild injection site irritation and occasional headaches show up regularly, matching the trial data. Some community self-experimenters report using doses far below the 4mg trial standard, sometimes in the hundreds of micrograms, which makes it even harder to know what any individual report reflects at all.
Two recurring themes are worth flagging. Product quality complaints are frequent, covering warm shipping, questionable sourcing, and potency doubts. And confusion between ARA-290 and cibinetide, and between vial size and dose, appears constantly in the same threads. Some glowing testimonials on vendor sites read as commercially influenced and should be discounted accordingly.
Where to Buy ARA-290
Sourcing matters more with ARA-290 than with most peptides, for a specific reason. It is only 11 amino acids, several vendors have been caught publishing the wrong sequence on their own product pages, and there is no way to eyeball whether a white powder is the right compound. Certificates of analysis are the only real check.
Our pick is Amino Club’s ARA-290 10mg. Every batch goes through 7 rounds of third-party testing with full COAs published, which is more verification than most of this market offers. It is $49.99 and comes to roughly $39.99 with code BRAINFLOW for 20 percent off. Whatever you choose, buy from somewhere that publishes real third-party certificates, and treat it as sold for research use only.
ARA-290 FAQ
Does ARA-290 relieve chronic pain?
The honest answer is mixed. Symptom scores and structural nerve markers improved significantly across multiple trials. Raw pain-intensity ratings, the most direct pain measure, often improved by similar amounts on placebo, and the largest trial’s pain endpoint did not reach statistical significance. Treat it as a compound with real evidence for nerve repair and promising but unproven evidence for pain relief specifically.
How long does ARA-290 take to work for nerve pain?
Trials measured changes over 28 days, and in one study the symptom improvement was still present nine months later. Community reports usually describe changes over two to three weeks. It behaves like a slow repair signal rather than an immediate painkiller.
Is ARA-290 the same as cibinetide?
Yes, identical molecule. ARA-290 is the developer’s code name and cibinetide is the official pharmaceutical name used in clinical trials and regulatory documents. Research-market ARA-290 is the same intended compound but not manufactured to pharmaceutical standards.
Does ARA-290 help fibromyalgia?
No trial has tested it. Some fibromyalgia patients show small fiber neuropathy, which makes the mechanism plausible, but that is a reasonable hypothesis, not evidence. Nobody has studied ARA-290 in a fibromyalgia population.
Is ARA-290 FDA approved?
No. It is not approved by the FDA or any other regulator worldwide. It holds orphan drug and Fast Track designations for sarcoidosis-related use, which are development incentives rather than approvals, and development has stalled with no active sponsor.
Is ARA-290 addictive like an opioid?
There is no mechanism for dependence or euphoria the way opioids create it, since ARA-290 does not act on opioid receptors at all. Its long-term safety with repeated use has never been studied, though, so “not addictive by mechanism” is not the same as “proven safe long-term.”
What dose was used in the trials?
4mg subcutaneously once daily for 28 days in most studies. A dose-ranging trial found 1mg underperformed and 8mg added nothing beyond 4mg. That documents what researchers administered under supervision, not a recommendation.
Does vial size mean dose?
No, and this is the most common mistake in the category. A 10mg vial contains 10mg of total peptide in the container. How much sits in any given volume depends entirely on how much liquid was added.
Where can I buy ARA-290?
We recommend Amino Club’s 7x-tested ARA-290, at $49.99 for 10mg and about $39.99 with code BRAINFLOW. Full certificates of analysis on every batch. Sold for research use only.
The Verdict on ARA-290
ARA-290 sits in a strange and interesting spot. By the standards of the research peptide market, its evidence base is exceptional, since it went through randomized placebo-controlled trials that measured actual nerve structure and found regrowth. Very few compounds in this space can say anything close to that.
By pharmaceutical standards, it is an unfinished story with a truly mixed pain result at its center. A hundred-odd patients, two narrow populations, a missed pain endpoint in the largest and most rigorous trial, a terminated eye study, no Phase 3, and a developer that went quiet before the work was done. That is not a failure so much as an abandonment, and abandonment usually says more about funding and rare-disease economics than about biology.
For someone with small fiber neuropathy who has run out of options, the mechanism is specific and the nerve-regrowth data is real, with a safety record over 28 days that stays mostly clean. Just go in knowing the pain relief itself, the thing most people want most, is the part of the evidence that stopped short of proof. For someone chasing recovery, longevity, fibromyalgia relief, or general anti-inflammatory benefits, no trial has studied that population, and the online enthusiasm is running well ahead of what any research has shown. Know which of those situations describes you before you spend a dollar.
ARA-290 (cibinetide) is not FDA-approved for any indication. All information here is for educational and research purposes only and is not medical advice.
ARA-290 is sold as a research compound for laboratory use only. Consult a qualified healthcare provider before beginning any protocol.
This article contains affiliate links. BrainFlow may earn a commission on qualifying purchases at no additional cost to the reader. We only recommend sources we trust.
